

# A Promising COVID-19 Antibody Treatment Enters Phase III Clinical Trials


## COVID-19 CLINICAL TRIALS IN THE UNITED STATES

Total number of clinical trials  
**624**

States with clinical trials  
**50**

### CLINICAL TRIALS ACROSS THE UNITED STATES

Explore the interactive map below to see what kind of COVID-19 research is going on in your community.



1-10 Trials   11-35 Trials   36-70 Trials   71-150 Trials   150+ Trials

While the global community eagerly awaits a COVID-19 vaccine, the science has progressed rapidly behind another form of preventative treatment: antibodies.

Because COVID-19 antibodies can be used to temporarily prevent infection, many in the scientific community believe that antibodies will provide a bridge until a safe and effective vaccine becomes widely available. In fact, [Dr. Anthony Fauci recently stated](#) that monoclonal antibodies are “almost a sure bet” to protect the body from the coronavirus.

There are over [620 clinical trials](#) for COVID-19 vaccines and therapeutics—including antibody treatments—taking place across the United States.

Yet, for this investment in innovative treatments to continue, policymakers must support smart innovation policy and reject unnecessary regulations, [including price controls](#). This will ensure that innovative companies can discover and deliver the treatments and vaccines which coronavirus patients desperately need.

One company leading the way in the race to deliver effective antibody treatments is Eli Lilly. The company [started the first human trial](#) of its potential antibody treatment in the beginning of June—and the clinical research

has advanced rapidly in just two months. On Monday, Eli Lilly announced the company would [begin a Phase 3 trial](#) to test the antibody treatment in nursing homes.

Why nursing homes? The leading scientists and the innovative community recognize that we will only know if therapeutics are truly effective if they are tested in the communities most impacted by the disease. With a significant percentage of COVID-19-related deaths linked to nursing homes, there is an urgent need to test potential treatments in the most vulnerable populations among us.

If Eli Lilly’s antibody treatment proves successful, the drug could receive regulatory approval by the end of the year.

As Dr. Anthony Fauci said at a [recent U.S. Chamber event](#), we must follow the science. The Chamber believes the science will soon lead us to effective therapeutics and vaccines which place us on the return to work and health once again.

—Jonathan Weinberger, Executive Vice President, U.S. Chamber Global Innovation Policy Center